Skip to main content
. 2017 Aug 8;8(62):104745–104760. doi: 10.18632/oncotarget.20065

Table 2. Structures and RTKs inhibitory activities of title compounds (QDAU1-10, IC50, nM).

Compound R1 R2 VEGFR-2 Tie-2 EphB4
QDAU1 H 3-CF3 194 70.5 >500
QDAU2 H 3-Cl 57.9 83.9 >500
QDAU3 H 3-F >500 90.7 5.64
QDAU4 H 2-F 1.91 4.91 13.9
QDAU5 3-F 4-F 0.77 8.87 3.21
QDAU6 H 4-F 6.28 101 >500
QDAU7 H 4-OCF3 >500 258 >500
QDAU8 H -CH(CH3)2 41.5 >500 >500
QDAU9 4-Cl 3-CF3 15.8 19.6 24.4
QDAU10 H 4-CF3 50.7 52.7 >500
Sorafenib 0.55 4.65 3.00